

Special Issue

Predictive Biomarkers for Treatment Response for Head and Neck Cancers

Message from the Guest Editor

HNSCC is a heterogeneous disease originating from the epithelial cell layer of the upper aerodigestive tract. These epithelial tumors are caused by multiple genetic alterations and are the 7th most common type of cancer worldwide. Head and neck cancer treatments require different combinations of chemotherapy (including cisplatin), surgery, and radiotherapy, but treatment resistance and local recurrence are still significant problems. In recent years, inhibition of EGFR signaling with the monoclonal EGFR antibody cetuximab and checkpoint inhibitors has emerged as a new treatment strategy, but less than 1/3 of unselected patients respond to new combination therapies. Therefore, to increase overall survival in HNSCC patients, personalized targeted therapy is required, which depends on the establishment of novel biomarkers that can predict treatment response. This Special Issue aims to consolidate the bench-to-bedside journey for developing new predictive biomarkers for treatment response in HNSCC and their significance for clinical decision. We welcome submissions that will contribute with biomarkers/a panel of biomarkers used in the clinic for a more personalized treatment.

Guest Editor

Prof. Dr. Karin Roberg

The Department of Biomedical and Clinical Sciences, Linköping University, SE-581 85 Linköping, Sweden

Deadline for manuscript submissions

closed (28 February 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/84938

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)